Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3995 in Type 2 Diabetic Nephropathy
NCT01756716Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of apararenone in diabetic nephropathy (DN), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Dec 2012; status: completed.
02
Drugs
apararenone
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01756716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01756716.